IFNG and tuberculosis: Strengths of the study include enrolment in geographically distinct sites across South Africa that were representative of populations with different rates of IFNγ release assay positivity and tuberculosis disease, which were congruent with local rates of RISK11 positivity, although the sample size was not sufficient for analysis of signature performance or 3HP efficacy at site level.